Genetics of CD33 in Alzheimer's disease and acute myeloid leukemia

Human Molecular Genetics
Manasi MalikSteven Estus

Abstract

The CD33 single-nucleotide polymorphism (SNP) rs3865444 has been associated with the risk of Alzheimer's disease (AD). Rs3865444 is in linkage disequilibrium with rs12459419 which has been associated with efficacy of an acute myeloid leukemia (AML) chemotherapeutic agent based on a CD33 antibody. We seek to evaluate the extent to which CD33 genetics in AD and AML can inform one another and advance human disease therapy. We have previously shown that these SNPs are associated with skipping of CD33 exon 2 in brain mRNA. Here, we report that these CD33 SNPs are associated with exon 2 skipping in leukocytes from AML patients and with a novel CD33 splice variant that retains CD33 intron 1. Each copy of the minor rs12459419T allele decreases prototypic full-length CD33 expression by ∼ 25% and decreases the AD odds ratio by ∼ 0.10. These results suggest that CD33 antagonists may be useful in reducing AD risk. CD33 inhibitors may include humanized CD33 antibodies such as lintuzumab which was safe but ineffective in AML clinical trials. Here, we report that lintuzumab downregulates cell-surface CD33 by 80% in phorbol-ester differentiated U937 cells, at concentrations as low as 10 ng/ml. Overall, we propose a model wherein a modest effec...Continue Reading

References

Jan 5, 2002·Advances in Experimental Medicine and Biology·M C MingariL Moretta
Aug 12, 2003·Advances in Experimental Medicine and Biology·Joan AlbanellPere Gascón
May 27, 2004·The Journal of Biological Chemistry·Angela InácioLuísa Romão
Feb 22, 2005·BMC Molecular Biology·Xiaozhu ZhangAndrew J Sandford
Apr 29, 2005·Brain : a Journal of Neurology·Yang LiuKlaus Fassbender
Oct 28, 2006·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Yona LevitesTodd E Golde
Dec 24, 2008·Journal of Neuropathology and Experimental Neurology·Peter T NelsonWilliam R Markesbery
Sep 25, 2009·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Erin G Reed-GeaghanGary E Landreth
Nov 9, 2010·Genetic Epidemiology·Yun LiGonçalo R Abecasis
Jul 30, 2011·Molecular Neurodegeneration·Minerva M CarrasquilloSteven G Younkin
Nov 24, 2011·Current Hematologic Malignancy Reports·Joseph G Jurcic
Apr 17, 2012·PloS One·I-Fang LingSteven Estus
Feb 28, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Leslie MortlandJatinder K Lamba
May 3, 2013·The New England Journal of Medicine·UNKNOWN Cancer Genome Atlas Research NetworkGreg Eley
May 28, 2013·Nature Neuroscience·Elizabeth M BradshawPhilip L De Jager
Aug 16, 2013·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Manasi MalikSteven Estus
Nov 19, 2013·PloS One·Perry G RidgeUNKNOWN Alzheimer’s Disease Genetics Consortium
Jan 2, 2014·Human Molecular Genetics·Towfique RajElizabeth M Bradshaw
May 9, 2014·Blood Reviews·George S LaszloRoland B Walter

❮ Previous
Next ❯

Citations

Oct 7, 2015·Molecular Neurodegeneration·Manasi MalikSteven Estus
Jul 22, 2015·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Andrew J SaykinUNKNOWN Alzheimer's Disease Neuroimaging Initiative
Jun 14, 2017·Leukemia·C D GodwinR B Walter
Jun 24, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jatinder K LambaSoheil Meshinchi
Jul 25, 2018·Future Oncology·Mohammed GbadamosiJatinder K Lamba
Dec 3, 2017·The Journal of Cell Biology·David V HansenMorgan Sheng
Apr 6, 2019·Acta Neuropathologica·Steven EstusDavid W Fardo
Nov 13, 2019·Current Pharmaceutical Design·Jacek M WitkowskiTamas Fulop
Feb 13, 2020·Biochemical Society Transactions·William G KerrJohn D Chisholm
Sep 30, 2020·Expert Opinion on Biological Therapy·Benjamin H GoldensonEdward D Ball
Aug 10, 2016·Neurology. Genetics·Gail ChanElizabeth M Bradshaw
Nov 30, 2018·Frontiers in Aging Neuroscience·Jacques HugonClaire Paquet
Apr 18, 2019·Molecular Neurobiology·Kelly N H NudelmanAndrew J Saykin
May 14, 2020·Translational Psychiatry·Thomaz Lüscher DiasHelder Imoto Nakaya
Oct 13, 2017·Blood·Frederick R Appelbaum, Irwin D Bernstein
Feb 24, 2020·Journal of Molecular Neuroscience : MN·Vasileios SiokasEfthimios Dardiotis
Aug 13, 2020·International Journal of Molecular Sciences·Laurène FenwarthNicolas Duployez
May 30, 2016·Alzheimer's & Dementia : Translational Research & Clinical Interventions·Linda J Van EldikKelly Bales
Jul 21, 2020·Oncology Reviews·Ruby DwivediDivya Mehrotra
Aug 13, 2020·Oncology Reviews·Saeid ShahrabiNajmaldin Saki
Oct 24, 2020·Scientific Reports·Motoaki YanaizuYoshihiro Kino
Feb 10, 2021·Current Opinion in Neurology·Ana Griciuc, Rudolph E Tanzi
Apr 20, 2021·Frontiers in Neuroscience·Punam Rawal, Liqin Zhao
May 16, 2021·Brain Research Bulletin·Kangkang YangWenzhe Li

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukaemia & RNA

Acute myeloid leukaemia (AML) is a common hematological type of cancer. As the population ages, there has been a rise in the frequency of AML. RNA expression has been used to see if there are different genetic profiles that exist within AML and whether these may underpin the variations in survival rates. Here is the latest research on AML and RNA.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Alzheimer's Disease: Genetics

Alzheimer's disease is a neurodegenerative disease. Discover genetic and epigenetic aspects of Alzheimer’s disease, including genetic markers and genomic structural variations with this feed.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.